| Juvenile rheumatoid arthritis
Hyrimoz vs Celebrex
Side-by-side clinical, coverage, and cost comparison for juvenile rheumatoid arthritis.Deep comparison between: Hyrimoz vs Celebrex with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCelebrex has a higher rate of injection site reactions vs Hyrimoz based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Celebrex but not Hyrimoz, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Hyrimoz
Celebrex
At A Glance
SC injection
Every other week
TNF-alpha antagonist
Oral
Once or twice daily
COX-2 inhibitor
Indications
- Rheumatoid Arthritis
- Juvenile rheumatoid arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis Vulgaris
- Hidradenitis
- Uveitis
- Degenerative polyarthritis
- Rheumatoid Arthritis
- Juvenile rheumatoid arthritis
- Ankylosing spondylitis
- Primary dysmenorrhea
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.
Juvenile rheumatoid arthritis Weight-based SC dosing every other week for patients >=2 years: 10 mg (10 to <15 kg), 20 mg (15 to <30 kg), or 40 mg (>=30 kg); same dosing applies to pediatric uveitis patients.
Crohn Disease Adults: 160 mg on Day 1, 80 mg on Day 15, then 40 mg SC every other week starting Day 29; pediatric patients >=6 years receive weight-based loading doses followed by 20 or 40 mg every other week.
Ulcerative Colitis Adults: 160 mg on Day 1, 80 mg on Day 15, then 40 mg SC every other week starting Day 29; discontinue if no clinical remission by Day 57.
Psoriasis Vulgaris, Uveitis 80 mg initial SC dose, then 40 mg every other week starting one week after initial dose.
Hidradenitis Adults: 160 mg Day 1, 80 mg Day 15, then 40 mg every week or 80 mg every other week SC starting Day 29; adolescents >=12 years receive weight-based dosing (80 mg Day 1 for 30 to <60 kg, or 160 mg Day 1 for >=60 kg).
Degenerative polyarthritis 200 mg once daily or 100 mg twice daily, oral.
Rheumatoid Arthritis 100 mg to 200 mg twice daily, oral.
Juvenile rheumatoid arthritis 50 mg twice daily for patients 10-25 kg; 100 mg twice daily for patients >25 kg, oral.
Ankylosing spondylitis 200 mg once daily or 100 mg twice daily, oral; if no effect after 6 weeks, may trial 400 mg daily.
Primary dysmenorrhea 400 mg initially, followed by 200 mg if needed on day 1; 200 mg twice daily on subsequent days, oral.
Contraindications
—
- Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib or any components of the drug product
- History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs
- Setting of CABG surgery
- Demonstrated allergic-type reactions to sulfonamides
Adverse Reactions
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, sinusitis, nausea, abdominal pain, back pain, urinary tract infection, flu syndrome, accidental injury, hypertension.
Serious Serious infections (pneumonia, septic arthritis, erysipelas, cellulitis, diverticulitis, pyelonephritis), malignancies, hypersensitivity reactions, hepatitis B reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity.
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, systemic vasculitis, deep vein thrombosis.
Most common (>=2%) Headache, dyspepsia, upper respiratory infection, diarrhea, sinusitis, abdominal pain, nausea, back pain, peripheral edema, rhinitis, pharyngitis, rash, flatulence, dizziness, insomnia.
Serious Cardiovascular thrombotic events, GI bleeding/ulceration/perforation, hepatotoxicity, hypertension, heart failure and edema, renal toxicity and hyperkalemia, anaphylactic reactions, serious skin reactions, hematologic toxicity.
Postmarketing Vasculitis, deep venous thrombosis, angioedema, liver necrosis, hepatic failure, agranulocytosis, aplastic anemia, pancytopenia, aseptic meningitis, fatal intracranial hemorrhage, interstitial nephritis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, DRESS, AGEP, fixed drug eruption.
Pharmacology
TNF-alpha antagonist; adalimumab-adaz is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, also lysing surface TNF-expressing cells in vitro in the presence of complement.
Celecoxib is a selective COX-2 inhibitor that reduces prostaglandin synthesis in peripheral tissues and the CNS, producing analgesic, anti-inflammatory, and antipyretic effects; at therapeutic doses it does not inhibit platelet aggregation or prolong bleeding time.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Hyrimoz
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Celebrex
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (4/12) · Qty limit (11/12)
UnitedHealthcare
Hyrimoz
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Celebrex
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Hyrimoz
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Celebrex
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Hyrimoz.
No savings programs available for Celebrex.
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HyrimozView full Hyrimoz profile
CelebrexView full Celebrex profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.